Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

John Christianson, Associate Professor at NDORMS, has been awarded a £2 million Cancer Research UK Senior Cancer Research Fellowship to explore new treatments for patients with multiple myeloma.

Cancer cells are often hallmarked by stress but take advantage of intrinsic protein homeostasis mechanisms to increase their resistance to stress-induced cell death. Multiple myeloma (MM) cancer cells rely heavily on endoplasmic reticulum-associated degradation (ERAD) to decrease the toxic levels of misfolded proteins that cause stress. Current therapeutic agents create more stress to induce MM cell death, but the robust and dynamically responsive ERAD mechanism elevates resistance to them which unwittingly supports cancer progression. The research will build on John’s previous work in proteostasis and ubiquitin biology to establish ERAD mediated by the Hrd1 ubiquitin ligase complex as a new therapeutic target in cancer. 

“This Fellowship is going to allow me to explore a new strategy for cancer intervention,” said John. “By understanding the fundamental nature of complexes responsible for protein degradation and the dynamic adaptability of quality control mechanisms, we can leverage that insight to develop compounds that impair or augment ERAD as a way to stop cancer cells from being able to grow.”

John has become a world-leader in his field researching the molecular mechanisms underpinning protein quality control in the ER, and in particular how specific substrates are identified and degraded by ER-associated ubiquitin ligases. 

Head of Department Professor Andrew Carr commented: “This exciting programme has the potential to lay the groundwork for the identification of new targets that may prove valuable for therapeutic intervention in cancer and other diseases associated with dysfunctional proteostasis, such as diabetes and neurodegeneration.”

Cancer Research UK Senior Fellowships support group leaders to further develop their own research programme and build their reputation as a world-leader in their cancer research field.

The research will start in January 2020 and run for six years.

Similar stories

NIHR Fellowships awarded to NDORMS researchers

Congratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships

ORUK Early Career Research Fellowship awarded to NDORMS researcher

Congratulations to Jack Tu who has been awarded an Orthopaedic Research UK Early Career Research Fellowship to explore the cause of knee pain after total knee replacement.

OCTRU - delivering answers to important clinical questions

The Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report

Unhelpful thoughts about fracture symptoms hinder recovery

The importance of mindsets and feelings about fracture symptoms have been shown to be a key factor in recovery of musculoskeletal conditions.

Fat tissues can play a protective role against inflammation in the intestine

A new study in The EMBO Journal has revealed how fat tissues might provide a protective role in intestinal inflammation opening new lines of research into the treatment of inflammatory bowel diseases.

NDORMS researchers awarded Sir Henry Wellcome Fellowships

Kennedy Institute researchers Mariana Borsa and Edward Jenkins have both been awarded Sir Henry Wellcome Postdoctoral Fellowships, which give recently qualified postdoctoral researchers the opportunity to start independent research careers.